INTRODUCTION
============

Meningioma originates from meningothelial cells of the arachnoid and is usually attached to the dura. It accounts for approximately 13%\~30% of primary intracranial tumor in adults. About 20%\~30% of meningioma occurs in the skull base. Most are benign and slow-growing tumors, and immediate intervention is not often needed \[[@B1][@B2][@B3]\]. However, if there is a clear tumor progression or any progressive or newly developed clinical symptoms, treatment is indicated. The goal of meningioma treatment is to minimize tumor progression or recurrence with low treatment-associated morbidity. Although the mainstay of meningioma treatment is surgical resection, many patients with skull base meningioma often fail to achieve complete resection without significant neurologic deficit due to the frequent involvement of cavernous sinus or cranial nerve, or close proximity to optic nerve or chiasm\[[@B4][@B5][@B6][@B7]\]. The progression rate after incomplete resection of Simpson grade III or higher has been reported to be 30% at 5 years, 60% at 10 years, and 90% at 15 years \[[@B8][@B9][@B10]\]. Despite the recent advances in microsurgical technique, the morbidity and mortality after surgical resection of skull base meningioma is still high \[[@B11][@B12][@B13]\].

Radiotherapy (RT) is safe and effective as a primary treatment for inoperable meningioma or adjuvant treatment for recurrent tumor after surgical resection \[[@B14][@B15]\]. Conventional radiotherapy has shown a 10-year tumor control rate exceeding 80% in large residual tumors or progressive growing masses \[[@B16][@B17]\]. Fractionated stereotactic RT (FSRT) was developed to reduce the high radiation dose administered to the surrounding normal brain tissue. FSRT has a similar therapeutic outcome compared to conventional RT \[[@B18][@B19]\]. For smaller tumors, stereotactic radiosurgery (SRS) such as a linear accelerator or Gamma Knife radiosurgery (GKS), has equivalent local control rates and acceptable toxicity \[[@B20][@B21][@B22][@B23]\]. However, SRS is limited in effectiveness for tumors close to the critical structures or tumors having a large volume, because of the radiosensitivity of these structures to a single large radiation dose. Multi-session or fractionated radiosurgery can be attractive and noninvasive treatment options for large residual or recurrent, inoperable skull base meningiomas. Hypofractionated radiosurgery can reduce the risk of late side effects because it allows normal tissue repair between fractions while delivering high dose per fraction \[[@B24]\]. In addition, reoxygenation and reassortment between fractions can improve tumor control by increasing cell kill. Colombo et al. \[[@B25]\] reported their experience of hypofractionated radiosurgery for meningioma patients who were unable to have single-session SRS using a Cyberknife with up to five fractionations. The authors reported a satisfactory tumor volume control rate of approximately 96.5% during the median 30-month follow-up period. However, as far as we know, there are few reports of fractionated radiosurgery for meningioma using GKS. While the Cyberknife and other linear accelerator-based systems perform multisession radiosurgery with 80% prescription isodose, the GKS Extend can give a higher maximum and cumulative radiation dose to the treatment volume using 50% isodose line \[[@B26]\]. We present our experience on the feasibility, neurological outcome, tumor control, and complication rate of hypofractionated GKS (FGKS) in consecutive days with the same Leksell® frame for large-sized skull base meningioma.

MATERIALS AND METHODS
=====================

Patient population
------------------

A review of our records revealed 149 consecutive patients with intracranial meningioma, who underwent FGKS at Seoul National University Hospital (SNUH) between November 2009 and June 2015. The International Review Board of SNUH approved this retrospective study and waived the requirement for informed consent considering the retrospective design of the study. FGKS was considered for the large skull base tumors adjacent to eloquent area or critical organs. The clinical symptoms were not severe in a large number of patients, and it was difficult to try surgical resection with high morbidity rates.

Of the 149 patients, 52 had large skull base meningioma ≥10 cm^3^. To clarify the efficacy of FGKS as an initial treatment option for large skull base meningioma, we excluded 27 patients who had previous surgical resection with or without adjuvant radiation, and 2 patients with prior radiosurgery. The remaining 23 patients were included. The clinical characteristics of the patients are summarized in [Table 1](#T1){ref-type="table"}. Single lesion was noted in 20 patients and 3 patients had multiple lesions.

Of the 23 patients with large skull base meningiomas, 6 were male (26%) and 17 were female (74%), with a mean age of 65 years (range 54\~80 years). All patients were diagnosed as meningioma based on clinical and characteristic radiologic findings by neurosurgeons and neuroradiologists. Alteration in function of cranial nerves (CNs) III, IV, V, or VI was the most common neurological deficit on presentation. The mean volume of tumors prior to radiosurgery was 21.63±15.46 cm^3^ (median, 15.1 cm^3^; range, 10.09\~71.42 cm^3^).

Radiosurgical technique
-----------------------

Gamma knife radiosurgery was performed with the Leksell Gamma Knife model Perfexion (Elekta Instrument AB, Stockholm, Sweden) using Leksell Gamma Plan (Elekta, Stockholm, Sweden). Gadolinium-enhanced T1-weighted and/or T2-weighted magnetic resonance imaging (MRI) was done with all patients, with a thin slice thickness of 1 to 1.5 mm. MRI data were digitized and transferred to the treatment planning system (Leksell Gamma Plan) through a picture archiving and communication system. GKRS planning was performed using axial images supplemented with reconstructed coronal and sagittal MRI. The radiosurgical parameters are presented in [Table 2](#T2){ref-type="table"}. The median total margin dose and marginal dose per fraction were 18 Gy (range, 15\~20 Gy) and 6 Gy (range, 5\~6 Gy), respectively. Patients underwent three or four fractionations in consecutive days with the same Leksell® frame. Tumor volumes were measured in follow-up images using the Osiris program (version 4.8; Service of Medical Informatics, Geneva University Hospital, Geneva, Switzerland), which allows the measurement of three-dimensional volume on the basis of MR images.

Radiological and clinical follow-up
-----------------------------------

Most patients had follow-up clinical evaluations 1, 3, 6, and 12 months after GKRS and then annually until 5 years after radiosurgery and every 2 months thereafter. At each follow-up visit, a neurological examination was performed to evaluate for new neurological deficits, and neuroimaging studies were reviewed to assess tumor response by both a neurosurgeon and neuroradiologist. Radiographic change of tumor volume was defined as decrease (≤85% of the initial volume), stable (85%\~115% of the initial volume), or increase (≥115% of the initial volume). The presence of peritumoral edema and radiation necrosis was defined as a newly appeared high signal in T2-weighted image and a loss of contrast enhancement in the center of the tumor, respectively. Clinically, the improvement or deterioration of pre-existing symptoms and the presence of newly appeared neurological symptoms were investigated. Favorable outcome was defined as tumor volume decrease or stable with no deterioration of neurologic symptoms or newly developed neurologic deficit, and unfavorable outcome was defined as increased tumor volume or exacerbation of neurologic symptoms.

Statistical analyses
--------------------

Overall survival and actuarial local tumor control rates were calculated using the Kaplan-Meier methods. The Cox proportional hazard model with the backward stepwise method was used for multivariate analyses and the results are presented as the hazard ratio (HR) and 95% confidence intervals (CI) as appropriate. The following dependent variables were assessed in univariate and multivariate analysis: tumor-free progression, worsening or new decline in neurological function, and favorable outcome. Clinical covariates predicting new or worsening decline in neurological function with a univariate p value \<0.20 were included in multivariable logistic regression analysis. Clinical covariates predicting unfavorable outcome with a univariate p value \<0.20 were included in multivariable logistic regression analysis. All the statistical analyses were performed with commercially available software (SPSS version 18.0; SPSS Inc., Chicago, IL). Statistical significance was accepted at p\<0.05 level.

RESULTS
=======

Radiologic outcome
------------------

The mean follow-up duration was 38 months (range, 17\~78). At the last follow-up, the tumor volume was stationary in 15 patients (65.2%), and decreased in 8 patients (34.8%). No patient experienced failure to control tumor volume. The mean tumor volume decreased significantly from 21.63±15.46 cm^3^ to 19.75±15.70 cm^3^ (p=0.000). [Fig. 1](#F1){ref-type="fig"} shows the tumor volume change in all patients. One patient (4.3%) had a peritumoral edema prior to FGKS. Following radiosurgery, 2 patients (9.0%) had new or worsening edema within 18 months of treatment. Of the 2, one patient had progression of preexisting edema and the other patient developed edema following radiosurgery. There was no symptomatic edema requiring further management and edema spontaneously improved without steroid in both patients. Central necrosis was detected in 2 patients (8.7%). Neither experienced tumor recurrence or secondary malignancy after radiosurgery.

Clinical outcome
----------------

Before FGKS, 6 patients (26%) complained of cranial neuropathy and 17 patients (74%) had no cranial neuropathy. The most common cranial neuropathy was visual field defect (3 patients, 13%), followed by trigeminal neuralgia (2 patients, 8.7%), hearing difficulty (1 patients, 4.3%), and diplopia (1 patients, 4.3%). All 6 patients with cranial neuropathy at the time of FGKS were improved at the last clinical follow-up. Following FGKS, 5 patients (21.7%) had new cranial neuropathy. In all cases, the neuropathy was transient, and included trigeminal neuralgia/facial numbness in 3 patients (18%), dysphagia in one patient (6%), and visual dimness in one patient (6%). Descriptions of clinical status are presented in [Table 3](#T3){ref-type="table"}. The most common newly developed cranial neuropathy during the follow-up period was trigeminal nerve deficit. Permanent cranial neuropathy did not occur. We did not experience any vascular injury of brainstem ischemia caused by radiosurgery.

Other pre-FGKS clinical symptoms were headache (5 patients, 21.7%), dizziness (4 patients, 17.4%), seizure (one patient, 4.3%), and weakness (one patient, 4.3%). Three patients with headache, seizure, and weakness remained unchanged, but the other patients\' symptoms improved during the follow-up period ([Table 3](#T3){ref-type="table"}).

Of the 23 patients, 9 were followed up with continuous basal hormone test and visual field test from at the time of FGKS over the follow-up period. Of them, one patient showed thyroid stimulating hormone (TSH) depletion in the laboratory finding without associated clinical symptoms. The patient has been under follow-up without hormone replacement treatment. One patient revealed a central visual field defect after 1 month after FGKS, but he recovered spontaneously after 5 months.

The mean Karnofsky Performance Status score at pre-FGKS and the last clinical follow-up was 97.0±10.4 points (median, 100) and 98.6±6.9 (median, 100) points, respectively. To the last follow-up, 22 patients maintained their daily living and job activities at the same level after FGKS. One patient who could not stand due to associated hydrocephalus before FGKS improved to walk with assist after FGKS followed by a ventriculoperitoneal (VP) shunt.

Complications and further treatments following FGKS
---------------------------------------------------

One patient (4%) underwent VP shunt surgery. This patient with cerebellopontine angle meningioma complained of voiding difficulty and gait disturbance, and the symptoms related with hydrocephalus improved after VP shunt which was performed at post-FGKS 5 months. There was no mortality during the follow-up period.

Overall outcome
---------------

We defined favorable outcome as no tumor progression and no new or developed neurologic deficit. There was no patient with tumor progression, but 5 patients (21.7%) experienced neurological deficit, which is transient or permanent, were classified as unfavorable outcome group. The remaining 18 patients (78.2%) were classified as favorable outcome group. [Table 4](#T4){ref-type="table"} represents an analysis of factors that predict an occurrence of unfavorable outcome. Factors including age older than 70 years, male gender, tumor location, newly developed peritumoral edema or central necrosis, total marginal dose, and tumor volume were analyzed to figure out the effect on unfavorable outcome. There were no statistically significant factors in univariate analysis, which might be caused by too small cohort.

Case presentation
-----------------

A 68-year-old man without a medical history was referred for the management of incidentally found petroclival meningioma. At the time of admission, the patient did not have any specific symptom or cranial neuropathy. On MRI, a dural based enhancing mass with iso-signal on T1-weighted and high signal intensity T2-weighted was found in the petroclival region. The volume of tumor mass was 17.8 cm^3^. FGKS was performed for 3 consecutive days considering the age of patient, large tumor volume, and petroclival location. Radiosurgical parameters were: total marginal dose 18 Gy in three fractionations, isodose line 50%, and shot 33. At 6 months after FGKS, the patient complained of transient facial numbness but the symptom disappeared spontaneously without any special management. On MRI at 6 months post-FGKS, decreased size of tumor of 9.7 cm^3^ with decreased central enhancement, suggesting necrosis due to radiation, was identified. [Fig. 2](#F2){ref-type="fig"} shows serial MRI data. The basal hormone test and visual field test performed every year after FGKS remained normal. Tumor volume remained reduced and was 8.6 cm^3^ at the last follow-up at 54 month, which was 48.31% decrease compared to initial tumor volume.

DISCUSSION
==========

The goal of SRS in meningioma is local tumor control and preservation of neurological function \[[@B27]\]. SRS has shown satisfactory outcome with ≥90% tumor growth control rates \[[@B25][@B28][@B29]\]. In a long-term study of GKS with mean marginal dose of 14 Gy for 972 patients (1,045 tumors), the 10-year local control rate was 91%, 50%, and 17% in WHO grade I, II, and III, respectively \[[@B30][@B31]\]. A Mayo Clinic follow-up study of 190 patients with 206 meningiomas treated by median prescription dose 16 Gy found the 5- and 7-year survival rate of 94% and 92%. In SRS for meningioma, the effect of local control highly depends on radiation dose, and single fraction dose ≤15 Gy is less effective \[[@B32][@B33]\].

GKS is a radiosurgery usually performed in a single session. However, lesions adjacent to radiation-sensitive critical structures, such as the optic pathway, increase the risk of traditional single-session GKS. Large-sized lesions also increase the risk \[[@B34]\]. Currently, the concept of radiosurgery has been extended up to five fractionations. More studies on fractionation have been recently done, reflecting the interest in avoiding unwanted radiation to adjacent radio-sensitive structures while giving high-dose radiation to the target \[[@B26][@B35][@B36][@B37][@B38][@B39]\]. Fractionation is a method of delivering higher cumulative radiation dose to target while minimizing damage to normal tissues. It is hypothesized that sublethal damage is rapidly repaired in normal tissue \[[@B34][@B40]\].

Hypofractionated radiosurgery has shown similar efficacy and treatment related toxicity, as reported in single-session SRS. Studies on FGKS have include the use of 20 Gy in three to five fractions \[[@B41]\] and 25 Gy in five fractions \[[@B42]\]. Both studies usually targeted benign neoplasms adjacent to the optic pathway, and neither had visual toxicity. Despite the fact that fractionation reduces unwanted radiation to surrounding tissue, higher doses are required to achieve the same dose effect due to DNS repair and cell repopulation between fractions \[[@B43]\]. While the Cyberknife and other linear accelerator-based systems perform multisession radiosurgery with 80% prescription isodose, the GKS Extend system can give a higher maximum and cumulative radiation dose to the treatment volume using 50% isodose line \[[@B26]\]. Previous studies indicated that higher maximum dose and dose heterogeneity of target may play an important role in a highly beneficial radiobiologic pathway, especially in late-responding tissue such as benign tumors, resulting in delayed vascular response \[[@B44][@B45]\]. The dose heterogeneity of multisession GKS with 50% isodose line may be beneficial in the treatment of solid neoplasm, unlike the linear-accelerator based system, which is 80%\~90% isodose line \[[@B46]\]. FGKS will broaden the indication of intracranial radiosurgery that can be treated with GKS.

Skull base meningiomas have a poorer outcome of single-session GKS than meningiomas located in other sites. Studies published on long-term efficacy of radiosurgery for skull base meningioma have reported tumor control rates of 89% to 98% and acceptable complication rates of 4% to 14% \[[@B47][@B48][@B49][@B50][@B51]\]. Our group reported a long-term outcome of single-session GKS for skull base meningioma \[[@B52]\]. The 5-year actuarial tumor control rate was 90.2% and unfavorable outcome of cranial neuropathy occurred in 15.9%. The improvement of cranial neuropathy was 45.1%, especially, the meningioma located at cavernous sinus showed a high improvement rate even at low marginal dose of 12 Gy.

There are several reports of FSRT for large skull base meningiomas. Debus et al. \[[@B18]\] reported their experiences about FSRT for 189 patients with a mean tumor volume of 52.5 cm^3^. The median radiation dose was 56.8 Gy and the mean follow-up duration was 35 months. The actuarial tumor control rate of WHO grade I meningiomas was 97% at 5 years and 96% at 10 years. Clinical significant treatment-induced toxicity was 1.6%. Minniti et al. \[[@B19]\] reported obtained similar outcomes after FSRT for 52 large skull base meningiomas. The median gross tumor volume (GTV) was 35.4 cm^3^, and radiotherapy was performed in 30 daily fractions over 6 weeks to a total dose of 50 Gy. During the median follow-up period of 42 months, the progression-free survival (PFS) rate was 96% and 93% at 3 and 5 years, respectively. Clinically significant late neurological toxicity was reported in 5.5% of the patients.

Bria et al. \[[@B53]\] reported the results of hypofractionated radiosurgery using the CyberKnife for 73 meningiomas. Local failure occurred in 11 cases, and the 1-year survival rate was 95%, 71%, and 9% in WHO grade I, II, and III, respectively. Tumor-related symptoms improved in 60% of cases. Satisfactory outcome on tumor control with similar toxicity rates compared to single-session GKS were evident in this study and previously reported studies.

Starke et al. \[[@B54]\] reported their single-session GKS experiences for 75 large skull base meningiomas with a mean tumor volume of 14.1 cm^3^. The mean follow-up duration was 6.5 years, and the actuarial PFS rate was 90.3% (3-year), 88.6% (5-year), and 77.2% (10-year). The neurological function deteriorated in 17% of the patients. To overcome the limitations of single-session GKS, few authors have tried multi-session GKS for skull base meningiomas. Iwai et al. \[[@B55]\] performed two-stage GKS for large petroclival and cavernous sinus meningiomas with a median prescription dose of 9 Gy per session. The mean initial tumor volume was 16.8 cm^3^. After median follow-up duration of 39 months, 6 patients (86%) obtained local control, and 3 had symptom improvement. Tumor progression occurred in only one person. There was no toxicity associated with treatment. There was also a study of volume-staged GKS in large skull base meningiomas with mean volume of 13.2 cm^3^ \[[@B56]\]. The tumor margin dose at stage I and II was 13.5 Gy and 9 Gy, respectively. Although only 4 patients were included in the study, after the median follow-up period of 100.5 months, all 4 patients obtained tumor control and all neurological deficits that existed before GKS were improved.

The Stanford group reviewed the outcome of fractionated SRS using the Cyberknife for large benign skull base tumors, including 21 meningiomas \[[@B39]\]. For 34 large benign tumors with median tumor volume of 19.3 cm^3^, fractionated SRS with median prescription dose of 24 Gy was performed over two to five sessions. After 31 months of median follow-up period, fractionated SRS was effective and safe, with local control rate of 100% and symptom improvement rate of 21%. About 11.7% of patients required glucocorticoids treatment due to transient neurological worsening, but there was no permanent deficit.

To our knowledge, two reports included FGKS experiences for large skull base meningioma. In the published reports, FGKS was primarily considered for the tumors difficult to surgically access or tumors expected to have high complication rates after single GKS. Large meningiomas located in convexity, falx, or parasagittal sinus were included, because of the concern about the occurrence of extensive peritumoral edema after single GKS. Tumors adjacent to eloquent area or critical organs were also candidates for FGKS. Surgically inaccessible skull base meningiomas also became indications for FGKS. McTyre et al. \[[@B57]\] included 15 cases of meningioma ≥10 cc, attached to the optic pathway, or had previously undergone single-session GKS. Recently, a study was published on the comparison of single-session GKS (n=42) and FGKS (n=28) for meningiomas ≥10 cm^3^ \[[@B58]\]. The FGKS group also included 16 skull base meningiomas. The mean tumor volume of single-session GKS and FGKS was 15.2 cm^3^ and 21 cm^3^, respectively. The FGKS group showed a higher overall 5-year tumor control rate than the single-session GKS group, without statistical significance (92.9% vs 88.1%, p=0.389).

In this study, the overall tumor control rate of skull base meningioma over mean follow-up duration of 38 months was 100%. Although the mean follow-up duration was relatively short, FGKS revealed considerable tumor control rates compared to single-session radiosurgery or conventional radiotherapy. Our group reported on the long-term outcome and growth rate of subtotally resected petroclival meningiomas in 2000 \[[@B59]\]. A total of 38 cases were followed for a mean of 47.5 months. The 5-year PFS rate was 60% and the median PFS survival time was 66 months. Based on these results, we have proposed subtotal resection with or without radiation or radiosurgery for the treatment of skull base meningioma. However, with the development of the radiosurgery technique and the increase in safety and efficacy, we experienced better results after FGKS as an initial treatment rather than surgical resection for large skull base meningioma.

Single-session GKS or FGKS overcomes tumor cell redistribution or reoxygenation of hypoxic cells within the cell cycle. Dividing a single dose into fractions reduces damage to normal tissue by restoring sublethal damage between fractions and allows cell repopulation. However, FGKS should also be performed with consideration of normal tissue embedded within radiosurgical target. The effect of dose and fractionation on normal tissue can be assessed using a linear quadratic cell survival curve model. In this model, the α/β ratio reflects the cell response to changes in the radiation fraction size. Tissues with low α/β ratio, such as normal brain, are more sensitive to larger dose fractions. Benign tumors such as meningioma have a low α/β ratio ≤3, so there is little benefit from fractionation and a single or hypofractionated regimen is preferred. Single session GKS for WHO grade I tumors has achieved a tumor control rate ≥90% using a dose of 14 Gy at 50% isodose line. In the FKGS for large skull base meningioma, we have tried a 3 or 4 fraction with a lower prescription dose, considering that the lesions are adjacent to the surrounding normal eloquent brain tissue or cranial nerve. The treatment dose given per fraction was determined to obtain the same biologically equivalent dose as in single session GKS using a BED calculation algorithm.

Symptomatic peritumoral edema has been reported on an average of 5%\~10% after radiosurgery or conventional radiotherapy \[[@B31][@B60][@B61][@B62]\]. Among the 23 patients who underwent FGKS, progression of the preexisting edema or newly developed edema was found in 2 patients, but there was no symptomatic edema. In previous studies, post-radiosurgical edema or necrosis was associated with tumor volume control \[[@B63]\], but we did not find any correlation between them in this study.

FKGS showed satisfactory results in clinical aspects, especially in facial pain. Two patients who had trigeminal neuralgia experienced a dramatic facial pain improvement after FGKS. This is consistent with previous findings that the fractionated approach is beneficial for tumor-associated trigeminal neuralgia \[[@B64][@B65][@B66][@B67]\]. After FGKS, there was no exacerbation of pre-existing cranial neuropathy, and 5 patients experienced newly developed cranial neuropathy but all of them was transient finding and improved spontaneously. We did not experience an occurrence of permanent neurologic deficit.

Our main concern was that whether the patients could tolerate the procedure well with the fixation of stereotactic frame for 3 or 4 consecutive days. All patients tolerated the pain and headache. Another concern about the movement of target in each fraction was resolved with the use of scout images. Since the introduction of ICON™ in March 2016, more patients have received FGKS using mask immobilization comfortably without pain. Considering the similar tumor control rate to single-session GKS and the satisfactory clinical outcome, FGKS is expected to become useful in large-sized skull base lesions including meningioma.

This study has some limitations resulting from its retrospective design and heterogeneous meningioma entities. We started the FGKS relatively recently and the follow-up duration is short. This study has no control group, and the comparison of efficacy and toxicity between single and fractionated GKS due to the small size of cohort. Another drawback is that there is no information on histology and proliferation indices, because radiosurgery was the initial treatment for meningioma diagnosed by imaging only. Very little is known about the optimal dose and fractionation regimen. FGKS using mask immobilization has been growing, and optimal treatment regimen would be clarified. Despite performed using frame, this result reporting FGKS would be some help in implementing FGKS in the future. Further study about FGKS with follow-up exceeding 10 years and prospective design is necessary to identify the long-term results and radiation-toxicity.

We analyzed the clinical results of FGKS performed as an initial treatment option for large skull base meningioma. FGKS produced satisfactory tumor control with functional preservation for large skull base meningiomas. FGKS could be an alternative option for large skull base lesions such as meningiomas, while avoiding high risks or surgical resection. Further prospective studies of large cohorts with long-term follow-up are required to clarify the efficacy in the tumor control and functional outcome as well as radiation toxicity.
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![Tumor volume change in all patients. At the last follow-up, the tumor volume was stationary in 15 patients (65.2%), and decreased in 8 patients (34.8%).](en-27-245-g001){#F1}

![Serial MRI of the patient who received hypofractionated Gamma knife radiosurgery (FGKS) for incidentally found petroclival meningioma. The initial volume of tumor mass was 17.8 cm^3^. FGKS was performed for 3 consecutive days. Radiosurgical parameters were: total marginal dose 18 Gy in 3 fractionation, isodose line 50%, and shot 33. At 6 months after FGKS, the patient complained of transient facial numbness but the symptom disappeared spontaneously without any special management. On MRI at post-FGKS 6 months, decreased size of tumor of 9.7 cm^3^ with decreased central enhancement, suggesting necrosis due to radiation, was identified.](en-27-245-g002){#F2}

###### Baseline characteristics of 23 patients with large skull base meningiomas treated with fractionated Gamma knife radiosurgery

![](en-27-245-i001)

  Parameters                                         Values
  -------------------------------------------------- ------------------
  Mean age, range (years)                            65 (54\~80)
  Gender: male/female                                6 (26%)/17 (74%)
  Pre-FGKS clinical manifestations                   
   Headache                                          5 (22%)
   Dizziness                                         4 (17%)
   Visual field defect                               3 (13%)
   Seizure                                           1 (4%)
   Cranial nerve deficit                             
    III/IV/VI                                        1 (4%)
    V                                                2 (9%)
    VII                                              0
    VIII                                             1 (4%)
    IX/X                                             0
    XI                                               0
    XII                                              0
   Weakness                                          1 (4%)
   Cognitive impairment                              0
  Location                                           
   Middle                                            
    Parasellar                                       2 (9%)
    Sphenoid ridge                                   4 (17%)
    Cavernous sinus                                  5 (22%)
   Posterior                                         
    Cerebellopontine angle                           9 (39%)
    Petroclival                                      2 (9%)
    Tentorial                                        1 (4%)
  Tumor volume                                       
   Mean±SD (cm^3^)                                   21.63±15.46
   Range (cm^3^)                                     10.09\~71.42
   10\~20 cm^3^                                      15 (65%)
   20\~30 cm^3^                                      5 (22%)
   30\~40 cm^3^                                      1 (4%)
   ≥40 cm^3^                                         2 (9%)
  Maximum tumor diameter (mm)                        
   Mean±SD                                           31.31±8.38
   Range                                             13.43\~52.79
  Mean clinical follow-up duration, range (months)   38 (17\~78)

###### Fractionated Gamma knife radiosurgery treatment parameters
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  Parameters                                      Values
  ----------------------------------------------- ----------------
  Median total marginal dose, range (Gy)          18, 15\~20
  Median marginal dose per fraction, range (Gy)   6, 5\~6
  Median maximum dose, range (Gy)                 12.1, 10\~68.6
  No. of fractionation, n (%)                     
   3                                              21 (91%)
   4                                              2 (9%)
  Median isodose line (%)                         50
  Median no. of shot, range                       27, 11\~49
  Fractionation schedule, n (%)                   
   6 Gy×3                                         18 (78%)
   5 Gy×3                                         3 (13%)
   5 Gy×4                                         2 (9%)

###### Cranial nerve deficits and other neurologic deficits before radiosurgery and changes after radiosurgery of 23 patients with large skull base meningiomas treated with FGKS

![](en-27-245-i003)

  Clinical manifestations   Baseline   Last follow-up   New deficits      
  ------------------------- ---------- ---------------- -------------- -- -------
  Headache                  5          4                1                 
  Dizziness                 4          4                                  
  Weakness                  1                           1                 
  Hypopituitarism                                                         1^\*^
  Seizure                   1                           1                 
  CN deficit                                                              
   II                       3          3                                  1
   III/IV/VI                1                           1                 
   V                        2          2                                  3
   VIII                     1          1                                  
   XII                                                                    1

^\*^Subclnical level.

###### Predictors of unfavorable outcome

![](en-27-245-i004)

  Variables                    Unfavorable outcome            
  ---------------------------- --------------------- -------- --------------
  Age \>70 y                                         0.9963   
  Male gender                  2.33                  0.4304   0.24\~19.82
  Middle fossa location        0.67                  0.6931   0.07\~4.99
  Posterior fossa location     1.50                  0.6931   0.20\~13.56
  Peritumoral edema                                  0.9953   
  Central necrosis             4.25                  0.3410   0.15\~124.90
  Total marginal dose ≥18 Gy                         0.9963   
  Tumor volume ≥20 cm^3^       1.33                  0.7822   0.15\~10.36
